← Leaderboards
Shuchi Gulati
University Of California At Davis
$1,044,288
Attributed
$1,044,288
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $261.1K · FY2022–25$500K$375K$250K$125K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,044,288 · 1
By mechanism
K08$1,044,288 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California At Davis
Same institution · by research overlap
- Xiao-Jing Wang$25,575,023
- Steven J Luck$17,993,420
- Ching-Hsien Chen$1,962,500
- Heather Michelle Fritz$542,852
- Richard M Schultz$25,036,810
Others in their field
Other Rising Stars on “Cohort”
- Gary Mays · Axle Informatics, Llc$58,129,860
- Brian Zavertnik · Palantir Technologies, Inc.$37,240,166
- Joan Grand · Mitre Corporation$32,826,287
- Bridget Murphy · Broad Institute, Inc.$23,600,775
- Suma Babu · Massachusetts General Hospital$22,928,184
- Sabrina Paganoni · Massachusetts General Hospital$22,928,184
Research focus
CohortComplexAdjuvant TherapyAdjuvantAdoptionBioinformaticsBiological MarkersBiomarker DevelopmentBiomarker IdentificationBiomarker ValidationBiopsyCaliforniaCancer BiologyCancer RecurrenceCareerCareer DevelopmentCategoriesCessation Of LifeCharacteristicsClear CellClear Cell Renal Cell CarcinomaClinically RelevantClinical TrialsCopper
Grant awards (4)
Combination of Transcriptomic and Metallomic Biomarkers for Risk Assessment in Locoregional Clear Cell Renal Cell Carcinoma$261,072
K08 · FY2025 · CA · contact PI
Combination of Transcriptomic and Metallomic Biomarkers for Risk Assessment in Locoregional Clear Cell Renal Cell Carcinoma$261,072
K08 · FY2024 · CA · contact PI
Combination of Transcriptomic and Metallomic Biomarkers for Risk Assessment in Locoregional Clear Cell Renal Cell Carcinoma$261,072
K08 · FY2023 · CA · contact PI
Combination of Transcriptomic and Metallomic Biomarkers for Risk Assessment in Locoregional Clear Cell Renal Cell Carcinoma$261,072
K08 · FY2022 · CA · contact PI